Abstract:Alcoholic hepatitis (AH) is an acute and severe form of alco1holic liver disease associated with high morbidity and mortality of 30-50% worldwide, severity ranging from asymptomatic derangement of liver biochemistries to fulminant liver failure or death. Rapidly progressing jaundice and coagulopathy in prolonged excessive alcohol abusers with or without fever, malnutrition, and tender liver are the clinical hallmarks. The prognostic models (Model for end-stage liver disease, Maddrey's discriminant function [MDF], age, serum bilirubin, INR, creatinine [ABIC], Glasgow Alcoholic Hepatitis Score [GAHS], Lille's Score) not only predict the short term mortality, but also guide the clinicians to choose appropriate specific therapy (corticosteroid or pentoxifylline) and as a stopping rule if there is no significant benefits of it. MDF Score is commonly followed in clinical practice, score of >32 would predict short term mortality of around 20-30% at 1 month and 30-40% within 6 months after presentation. The GAHS on day 1 can predict 28 day overall survival outcome accuracy of 81%, which is comparatively higher than MDF Score. Moreover, ABIC Score categorizes risk of deaths (based on 90 days) into low risks (0%), intermediate risk (30%), and high risk (75%). Corticosteroid and pentoxifylline have significant benefits in decreasing mortality (corticosteroid improves survival on 28 day and 84 day of 78% and 59%) in severe disease state (MDF >32 or Lille's Score >0.45 or GAHS >9). Corticosteroid is the initial treatment of choice with infections screening before initiating; however, pentoxifylline is better preferred in case of AH with severe infections and hepatorenal syndrome. Additionally, combination of corticosteroids and N-acetylcysteine decreases development of hepatorenal syndrome, infections, and short-term mortality. However, the Lille Score after corticosteroid therapy of >0.45 after day 7 indicates poor responders or >0.56 indicates null responders. Therefore, in these cases, either therapy has to be stopped or changed to pentoxifylline. In treatment failure cases, liver transplantation is the ultimate option. However, the facilitating of this service in most transplant centers is a challenge. Beside these specific therapies, alcohol abstinence and recommendation of nutritional supplements with high calorie, protein diet and vitamin E, C, thiamine regardless of other treatment plays a prime role in preventing disease progression and survival benefits even in pre and post-transplant cases.

Impact of Alcohol Drinking on the Clinical Progression and Outcome of Patients with Chronic Hepatitis C

Study on the relationship between alcohol consumption and cardiovascular disease risks

Relationship between alcohol consumption and risk factors for cardiovascular disease]

Alcohol Use and Treatment of Hepatitis C Virus: Results of a National Multicenter Study

T1864 Early Mortality of Alcoholic Hepatitis: A Review of Data from Placebo-Controlled Clinical Trials

A Prognostic Evaluation and Management of Alcoholic Hepatitis

Influence of drinking on progression of chronic hepatitis B and outcome of antiviral therapy

Effects of alcohol consumption on viral hepatitis B and C

Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C)

Associations Between Alcohol Use and Liver-Related Outcomes in a Large National Cohort of Patients With Cirrhosis

Early Mortality Of Alcoholic Hepatitis: A Review Of Data From Placebo-Controlled Clinical Trials

Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials.

Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease

The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization.

Alcohol consumption analysis among patients with liver disease in China.

Differences in complications between hepatitis B-related cirrhosis and alcohol-related cirrhosis

Progress in synergetic effects and mechanisms of alcohol consumption and hepatitis B infection on liver injury

Prevalence and impact of alcohol abstinence in alcohol‐associated cirrhosis: Systematic review and meta‐analysis

Analysis of clinical characteristics of alcoholic liver disease cases infected with hepatitis viruses

Differentiation between alcohol-associated cirrhosis and hepatitis B-associated cirrhosis based on hepatic complications and psychological symptoms